[Pathogenesis of migraine and mode of action of antimigraine agents].
D002560:Cerebrovascular Circulation / Q000187:drug effects; D004878:Ergotamine / Q000627:therapeutic use; D006632:Histamine / Q000378:metabolism; D006801:Humans; D008784:Methysergide / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy / Q000209:etiology*; D009638:Norepinephrine / Q000627:therapeutic use; D010649:Phenylalanine / Q000009:adverse effects; D011453:Prostaglandins / Q000009:adverse effects; D012701:Serotonin / Q000378:metabolism; D014439:Tyramine / Q000009:adverse effects
D011453:Prostaglandins; D012701:Serotonin; D010649:Phenylalanine; D006632:Histamine; D004878:Ergotamine; D009638:Norepinephrine; D014439:Tyramine; D008784:Methysergide
Pathogenèse de la migraine et mode d'action des antimigraineux